Hogdall C - Search Results

1

Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival.

Quaye L, Dafou D, Ramus SJ, Song H, Gentry-Maharaj A, Notaridou M, Hogdall E, Kjaer SK, Christensen L, Hogdall C, Easton DF, Jacobs I, Menon U, Pharoah PD, Gayther SA. Quaye L, et al. Among authors: hogdall e, hogdall c. Hum Mol Genet. 2009 May 15;18(10):1869-78. doi: 10.1093/hmg/ddp107. Epub 2009 Mar 6. Hum Mol Genet. 2009. PMID: 19270026

2

[15(S)-15-methyl-prostaglandin F2 alpha. A potent synthetic prostaglandin F2 alpha for treatment of postpartum atony].

Høgdall EV, Høgdall CK. Høgdall EV, et al. Among authors: hogdall ck. Ugeskr Laeger. 1991 Nov 11;153(46):3260-2. Ugeskr Laeger. 1991. PMID: 1957386 Danish. No abstract available.

3

[Treatment of severe postpartum atony with prostaglandin].

Høgdall CK, Høgdall E. Høgdall CK, et al. Among authors: hogdall e. Ugeskr Laeger. 1989 Sep 18;151(38):2410-3. Ugeskr Laeger. 1989. PMID: 2678650 Review. Danish.

4

[Tetranectin, a plasma and tissue protein--a prognostic marker of breast and ovarian cancer].

Høgdall CK, Christensen L, Clemmensen I. Høgdall CK, et al. Ugeskr Laeger. 1994 Oct 17;156(42):6190-5. Ugeskr Laeger. 1994. PMID: 7998355 Review. Danish.

5

Pre-operative plasma tetranectin as a prognostic marker in ovarian cancer patients.

Høgdall CK, Høgdall EV, Hørding U, Clemmensen I, Nørgaard-Pedersen B, Toftager-Larsen K. Høgdall CK, et al. Among authors: hogdall ev. Scand J Clin Lab Invest. 1993 Nov;53(7):741-6. doi: 10.3109/00365519309092579. Scand J Clin Lab Invest. 1993. PMID: 8272761

6

The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer.

Høgdall CK, Christensen L, Clemmensen I. Høgdall CK, et al. Cancer. 1993 Oct 15;72(8):2415-22. doi: 10.1002/1097-0142(19931015)72:8<2415::aid-cncr2820720820>3.0.co;2-n. Cancer. 1993. PMID: 8402458

7

Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients.

Høgdall EV, Høgdall CK, Christensen L, Glud E, Blaakaer J, Bock JE, Vuust J, Nørgaard-Pedersen B, Kjaer SK. Høgdall EV, et al. Anticancer Res. 2002 May-Jun;22(3):1859-64. Anticancer Res. 2002. PMID: 12168882

8

P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis.

Høgdall EV, Høgdall CK, Blaakaer J, Heegaard NH, Glud E, Christensen L, Bock JE, Nørgaard-Pedersen B, Wiik A, Kjaer SK. Høgdall EV, et al. APMIS. 2002 Aug;110(7-8):545-53. doi: 10.1034/j.1600-0463.2002.11007805.x. APMIS. 2002. PMID: 12390412

9

Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer.

Dehn H, Høgdall EV, Johansen JS, Jørgensen M, Price PA, Engelholm SA, Høgdall CK. Dehn H, et al. Acta Obstet Gynecol Scand. 2003 Mar;82(3):287-93. doi: 10.1034/j.1600-0412.2003.00010.x. Acta Obstet Gynecol Scand. 2003. PMID: 12694127 Free article.

10

K-ras alterations in Danish ovarian tumour patients. From the Danish "Malova" Ovarian Cancer study.

Høgdall EV, Høgdall CK, Blaakaer J, Christensen L, Bock JE, Vuust J, Glud E, Kjaer SK; Danish "Malova" Ovarian Cancer Study. Høgdall EV, et al. Gynecol Oncol. 2003 Apr;89(1):31-6. doi: 10.1016/s0090-8258(03)00005-2. Gynecol Oncol. 2003. PMID: 12694651

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

364 results

Search Page

Filters